Table of Content

1 Primary Immunodeficiency Drug Market Overview
1.1 Product Overview and Scope of Primary Immunodeficiency Drug
1.2 Primary Immunodeficiency Drug Segment by Type
1.2.1 Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2034)
1.2.2 Immunoglobulin
1.2.3 Antibiotic
1.2.4 Stem Cell
1.2.5 Other
1.3 Primary Immunodeficiency Drug Segment by Application
1.3.1 Global Primary Immunodeficiency Drug Market Value by Application: (2024-2034)
1.3.2 Antibody Deficiency
1.3.3 Cellular Immunodeficiency
1.3.4 Innate Immune Disease
1.3.5 Other
1.4 Global Primary Immunodeficiency Drug Market Size Estimates and Forecasts
1.4.1 Global Primary Immunodeficiency Drug Revenue 2018-2029
1.4.2 Global Primary Immunodeficiency Drug Sales 2018-2029
1.4.3 Global Primary Immunodeficiency Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Primary Immunodeficiency Drug Market Competition by Manufacturers
2.1 Global Primary Immunodeficiency Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Primary Immunodeficiency Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Primary Immunodeficiency Drug Average Price by Manufacturers (2018-2024)
2.4 Global Primary Immunodeficiency Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Primary Immunodeficiency Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Immunodeficiency Drug, Product Type & Application
2.7 Primary Immunodeficiency Drug Market Competitive Situation and Trends
2.7.1 Primary Immunodeficiency Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary Immunodeficiency Drug Players Market Share by Revenue
2.7.3 Global Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Immunodeficiency Drug Retrospective Market Scenario by Region
3.1 Global Primary Immunodeficiency Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Sales by Region: 2018-2029
3.2.1 Global Primary Immunodeficiency Drug Sales by Region: 2018-2024
3.2.2 Global Primary Immunodeficiency Drug Sales by Region: 2024-2029
3.3 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Revenue by Region: 2018-2029
3.3.1 Global Primary Immunodeficiency Drug Revenue by Region: 2018-2024
3.3.2 Global Primary Immunodeficiency Drug Revenue by Region: 2024-2029
3.4 North America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.4.1 North America Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.4.3 North America Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary Immunodeficiency Drug Market Facts & Figures by Country
3.5.1 Europe Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.5.3 Europe Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Immunodeficiency Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.7.1 Latin America Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.7.3 Latin America Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Immunodeficiency Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary Immunodeficiency Drug Sales by Type (2018-2029)
4.1.1 Global Primary Immunodeficiency Drug Sales by Type (2018-2024)
4.1.2 Global Primary Immunodeficiency Drug Sales by Type (2024-2029)
4.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Type (2018-2029)
4.2 Global Primary Immunodeficiency Drug Revenue by Type (2018-2029)
4.2.1 Global Primary Immunodeficiency Drug Revenue by Type (2018-2024)
4.2.2 Global Primary Immunodeficiency Drug Revenue by Type (2024-2029)
4.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Type (2018-2029)
4.3 Global Primary Immunodeficiency Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Primary Immunodeficiency Drug Sales by Application (2018-2029)
5.1.1 Global Primary Immunodeficiency Drug Sales by Application (2018-2024)
5.1.2 Global Primary Immunodeficiency Drug Sales by Application (2024-2029)
5.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Application (2018-2029)
5.2 Global Primary Immunodeficiency Drug Revenue by Application (2018-2029)
5.2.1 Global Primary Immunodeficiency Drug Revenue by Application (2018-2024)
5.2.2 Global Primary Immunodeficiency Drug Revenue by Application (2024-2029)
5.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Application (2018-2029)
5.3 Global Primary Immunodeficiency Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 ADMA Biologics, Inc.
6.1.1 ADMA Biologics, Inc. Corporation Information
6.1.2 ADMA Biologics, Inc. Description and Business Overview
6.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drug Product Portfolio
6.1.5 ADMA Biologics, Inc. Recent Developments/Updates
6.2 CSL Behring, LLC
6.2.1 CSL Behring, LLC Corporation Information
6.2.2 CSL Behring, LLC Description and Business Overview
6.2.3 CSL Behring, LLC Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 CSL Behring, LLC Primary Immunodeficiency Drug Product Portfolio
6.2.5 CSL Behring, LLC Recent Developments/Updates
6.3 Octapharma
6.3.1 Octapharma Corporation Information
6.3.2 Octapharma Description and Business Overview
6.3.3 Octapharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Octapharma Primary Immunodeficiency Drug Product Portfolio
6.3.5 Octapharma Recent Developments/Updates
6.4 Takeda Pharmaceutical Company
6.4.1 Takeda Pharmaceutical Company Corporation Information
6.4.2 Takeda Pharmaceutical Company Description and Business Overview
6.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product Portfolio
6.4.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.5 Grifols Biologicals, Inc.
6.5.1 Grifols Biologicals, Inc. Corporation Information
6.5.2 Grifols Biologicals, Inc. Description and Business Overview
6.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product Portfolio
6.5.5 Grifols Biologicals, Inc. Recent Developments/Updates
6.6 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Baxter Primary Immunodeficiency Drug Product Portfolio
6.6.5 Baxter Recent Developments/Updates
6.7 Kedrion Biopharma
6.6.1 Kedrion Biopharma Corporation Information
6.6.2 Kedrion Biopharma Description and Business Overview
6.6.3 Kedrion Biopharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Kedrion Biopharma Primary Immunodeficiency Drug Product Portfolio
6.7.5 Kedrion Biopharma Recent Developments/Updates
6.8 BPL Inc.
6.8.1 BPL Inc. Corporation Information
6.8.2 BPL Inc. Description and Business Overview
6.8.3 BPL Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 BPL Inc. Primary Immunodeficiency Drug Product Portfolio
6.8.5 BPL Inc. Recent Developments/Updates
6.9 Pharming Group
6.9.1 Pharming Group Corporation Information
6.9.2 Pharming Group Description and Business Overview
6.9.3 Pharming Group Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Pharming Group Primary Immunodeficiency Drug Product Portfolio
6.9.5 Pharming Group Recent Developments/Updates
6.10 Shire
6.10.1 Shire Corporation Information
6.10.2 Shire Description and Business Overview
6.10.3 Shire Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Shire Primary Immunodeficiency Drug Product Portfolio
6.10.5 Shire Recent Developments/Updates
6.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
6.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
6.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Description and Business Overview
6.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product Portfolio
6.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Immunodeficiency Drug Industry Chain Analysis
7.2 Primary Immunodeficiency Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Immunodeficiency Drug Production Mode & Process
7.4 Primary Immunodeficiency Drug Sales and Marketing
7.4.1 Primary Immunodeficiency Drug Sales Channels
7.4.2 Primary Immunodeficiency Drug Distributors
7.5 Primary Immunodeficiency Drug Customers
8 Primary Immunodeficiency Drug Market Dynamics
8.1 Primary Immunodeficiency Drug Industry Trends
8.2 Primary Immunodeficiency Drug Market Drivers
8.3 Primary Immunodeficiency Drug Market Challenges
8.4 Primary Immunodeficiency Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Primary Immunodeficiency Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Primary Immunodeficiency Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Primary Immunodeficiency Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Primary Immunodeficiency Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Primary Immunodeficiency Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Primary Immunodeficiency Drug Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Primary Immunodeficiency Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Primary Immunodeficiency Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Primary Immunodeficiency Drug, Product Type & Application
Table 12. Global Key Manufacturers of Primary Immunodeficiency Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Primary Immunodeficiency Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Primary Immunodeficiency Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Primary Immunodeficiency Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Primary Immunodeficiency Drug Sales Market Share by Region (2018-2024)
Table 19. Global Primary Immunodeficiency Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Primary Immunodeficiency Drug Sales Market Share by Region (2024-2029)
Table 21. Global Primary Immunodeficiency Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Primary Immunodeficiency Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Primary Immunodeficiency Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Primary Immunodeficiency Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Primary Immunodeficiency Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Primary Immunodeficiency Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Primary Immunodeficiency Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Primary Immunodeficiency Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Primary Immunodeficiency Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Primary Immunodeficiency Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Primary Immunodeficiency Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Primary Immunodeficiency Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Primary Immunodeficiency Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Primary Immunodeficiency Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Primary Immunodeficiency Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Primary Immunodeficiency Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Primary Immunodeficiency Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Primary Immunodeficiency Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Primary Immunodeficiency Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Primary Immunodeficiency Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Primary Immunodeficiency Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Primary Immunodeficiency Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Primary Immunodeficiency Drug Sales Market Share by Type (2018-2024)
Table 53. Global Primary Immunodeficiency Drug Sales Market Share by Type (2024-2029)
Table 54. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Primary Immunodeficiency Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2018-2024)
Table 59. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2024-2029)
Table 60. Global Primary Immunodeficiency Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Primary Immunodeficiency Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Primary Immunodeficiency Drug Sales Market Share by Application (2018-2024)
Table 63. Global Primary Immunodeficiency Drug Sales Market Share by Application (2024-2029)
Table 64. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Primary Immunodeficiency Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Primary Immunodeficiency Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Primary Immunodeficiency Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2018-2024)
Table 69. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2024-2029)
Table 70. ADMA Biologics, Inc. Corporation Information
Table 71. ADMA Biologics, Inc. Description and Business Overview
Table 72. ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. ADMA Biologics, Inc. Primary Immunodeficiency Drug Product
Table 74. ADMA Biologics, Inc. Recent Developments/Updates
Table 75. CSL Behring, LLC Corporation Information
Table 76. CSL Behring, LLC Description and Business Overview
Table 77. CSL Behring, LLC Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. CSL Behring, LLC Primary Immunodeficiency Drug Product
Table 79. CSL Behring, LLC Recent Developments/Updates
Table 80. Octapharma Corporation Information
Table 81. Octapharma Description and Business Overview
Table 82. Octapharma Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Octapharma Primary Immunodeficiency Drug Product
Table 84. Octapharma Recent Developments/Updates
Table 85. Takeda Pharmaceutical Company Corporation Information
Table 86. Takeda Pharmaceutical Company Description and Business Overview
Table 87. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product
Table 89. Takeda Pharmaceutical Company Recent Developments/Updates
Table 90. Grifols Biologicals, Inc. Corporation Information
Table 91. Grifols Biologicals, Inc. Description and Business Overview
Table 92. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product
Table 94. Grifols Biologicals, Inc. Recent Developments/Updates
Table 95. Baxter Corporation Information
Table 96. Baxter Description and Business Overview
Table 97. Baxter Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Baxter Primary Immunodeficiency Drug Product
Table 99. Baxter Recent Developments/Updates
Table 100. Kedrion Biopharma Corporation Information
Table 101. Kedrion Biopharma Description and Business Overview
Table 102. Kedrion Biopharma Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Kedrion Biopharma Primary Immunodeficiency Drug Product
Table 104. Kedrion Biopharma Recent Developments/Updates
Table 105. BPL Inc. Corporation Information
Table 106. BPL Inc. Description and Business Overview
Table 107. BPL Inc. Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. BPL Inc. Primary Immunodeficiency Drug Product
Table 109. BPL Inc. Recent Developments/Updates
Table 110. Pharming Group Corporation Information
Table 111. Pharming Group Description and Business Overview
Table 112. Pharming Group Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Pharming Group Primary Immunodeficiency Drug Product
Table 114. Pharming Group Recent Developments/Updates
Table 115. Shire Corporation Information
Table 116. Shire Description and Business Overview
Table 117. Shire Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Shire Primary Immunodeficiency Drug Product
Table 119. Shire Recent Developments/Updates
Table 120. Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
Table 121. Chengdu Rongsheng Pharmaceutical Co., Ltd Description and Business Overview
Table 122. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product
Table 124. Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Primary Immunodeficiency Drug Distributors List
Table 128. Primary Immunodeficiency Drug Customers List
Table 129. Primary Immunodeficiency Drug Market Trends
Table 130. Primary Immunodeficiency Drug Market Drivers
Table 131. Primary Immunodeficiency Drug Market Challenges
Table 132. Primary Immunodeficiency Drug Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Primary Immunodeficiency Drug
Figure 2. Global Primary Immunodeficiency Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Primary Immunodeficiency Drug Market Share by Type in 2022 & 2029
Figure 4. Immunoglobulin Product Picture
Figure 5. Antibiotic Product Picture
Figure 6. Stem Cell Product Picture
Figure 7. Other Product Picture
Figure 8. Global Primary Immunodeficiency Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Primary Immunodeficiency Drug Market Share by Application in 2022 & 2029
Figure 10. Antibody Deficiency
Figure 11. Cellular Immunodeficiency
Figure 12. Innate Immune Disease
Figure 13. Other
Figure 14. Global Primary Immunodeficiency Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Primary Immunodeficiency Drug Market Size (2018-2029) & (US$ Million)
Figure 16. Global Primary Immunodeficiency Drug Sales (2018-2029) & (K Units)
Figure 17. Global Primary Immunodeficiency Drug Average Price (US$/Unit) & (2018-2029)
Figure 18. Primary Immunodeficiency Drug Report Years Considered
Figure 19. Primary Immunodeficiency Drug Sales Share by Manufacturers in 2022
Figure 20. Global Primary Immunodeficiency Drug Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Primary Immunodeficiency Drug Players: Market Share by Revenue in 2022
Figure 22. Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Primary Immunodeficiency Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America Primary Immunodeficiency Drug Sales Market Share by Country (2018-2029)
Figure 25. North America Primary Immunodeficiency Drug Revenue Market Share by Country (2018-2029)
Figure 26. United States Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Primary Immunodeficiency Drug Sales Market Share by Country (2018-2029)
Figure 29. Europe Primary Immunodeficiency Drug Revenue Market Share by Country (2018-2029)
Figure 30. Germany Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific Primary Immunodeficiency Drug Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific Primary Immunodeficiency Drug Revenue Market Share by Region (2018-2029)
Figure 37. China Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Indonesia Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Thailand Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Malaysia Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Latin America Primary Immunodeficiency Drug Sales Market Share by Country (2018-2029)
Figure 47. Latin America Primary Immunodeficiency Drug Revenue Market Share by Country (2018-2029)
Figure 48. Mexico Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Brazil Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Argentina Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Middle East & Africa Primary Immunodeficiency Drug Sales Market Share by Country (2018-2029)
Figure 52. Middle East & Africa Primary Immunodeficiency Drug Revenue Market Share by Country (2018-2029)
Figure 53. Turkey Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. UAE Primary Immunodeficiency Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. Global Sales Market Share of Primary Immunodeficiency Drug by Type (2018-2029)
Figure 57. Global Revenue Market Share of Primary Immunodeficiency Drug by Type (2018-2029)
Figure 58. Global Primary Immunodeficiency Drug Price (US$/Unit) by Type (2018-2029)
Figure 59. Global Sales Market Share of Primary Immunodeficiency Drug by Application (2018-2029)
Figure 60. Global Revenue Market Share of Primary Immunodeficiency Drug by Application (2018-2029)
Figure 61. Global Primary Immunodeficiency Drug Price (US$/Unit) by Application (2018-2029)
Figure 62. Primary Immunodeficiency Drug Value Chain
Figure 63. Primary Immunodeficiency Drug Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed